Skip to main content
An official website of the United States government
Technology ID
TAB-4126

T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein

E-Numbers
E-176-2014-0
Lead Inventors
Hinrichs, Christian
Co-Inventors
Rosenberg, Steven
Applications
Therapeutics
Therapeutic Areas
Oncology
Infectious Disease
Development Stages
Clinical Phase I
Lead IC
NCI
ICs
NCI

Human papillomavirus (HPV) is a group of human viruses known to cause various malignancies. Of the group, HPV-16 is the most prevalent strain – an estimated 90% of adults have been exposed. HPV-16 is also the strain most commonly associated with malignancy, causing the vast majority of cervical, anal, vaginal, vulvar, and penile cancers. Currently, HPV-positive malignancies non-responsive to surgery or radiation are incurable and poorly palliated by existing systemic therapies. Thus, an alternative therapeutic approach for HPV-positive malignancies is needed. 

Researchers at the National Cancer Institute (NCI) developed a T cell receptor (TCR) that may be used in adoptive cell therapy to treat HPV-positive malignancies. The TCR confers high-avidity recognition of the HPV-specific E7 oncoprotein that drives malignant transformation in HPV-infected cells. Further, E7 is specific to and constitutively expressed by cancer cells, making it an ideal therapeutic target. The TCR targets human leukocyte antigen (HLA)-A*02-restricted epitope E711-19. The inventors successfully transduced T cells obtained from peripheral blood mononuclear cells (PBMCs) with this TCR. An ongoing Phase I/II clinical trial is investigating the efficacy of the E7-targeting TCR in treating HPV-positive malignancies.  

The NCI Center for Immuno-Oncology is actively seeking co-development partners and/or licensees for this E7-targeting TCR with therapeutic potential for HPV-positive conditions.  

Competitive Advantages:

  • FDA approval of another first-in-class TCR therapeutic demonstrates treatment benefit of approach 
  • FDA approval of another first-in-class TCR therapeutic decreases regulatory risk
  • High avidity for the HPV-specific E7 oncoprotein
  • Specifically recognize HLA-A*02-positive HPV-16 cancer cells
  • TCR can be used to transduce T cells isolated from PBMCs, an easily accessible source of human immune cells 

 

Commercial Applications:

  • Adoptive cell therapy against HPV-positive cancers
  • Treatment of HPV-related infections and premalignant conditions
  • Prevention of HPV-related infections and premalignant conditions
  • Detection of HPV-infected or transformed cells for diagnostic purposes

 

Request More Info

Licensing Contacts
Burke, Andrew
burkear@mail.nih.gov

Related Inventions

  • E-495-2013           TAB-3933
    T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein

Patents

  • US
    Provisional (PRV) 62/004,335
    Filed on 2014-05-29
    Status: Abandoned
  • Patent Cooperation Treaty
    (PCT) PCT/US2015/033129
    Filed on 2015-05-29
    Status: Expired
  • Canada
    National Stage 2950192
    Filed on 2015-05-29
    Status: Pending
  • Australia
    National Stage 2015266818
    Filed on 2015-05-29
    Status: Issued
  • Brazil
    National Stage BR112016027805-4
    Filed on 2015-05-29
    Status: Pending
  • China
    National Stage 201580031789.X
    Filed on 2015-05-29
    Status: Issued
  • European Patent
    National Stage 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Israel
    National Stage 248797
    Filed on 2016-11-07
    Status: Issued
  • Japan
    National Stage 2017-515021
    Filed on 2015-05-29
    Status: Issued
  • South Korea
    National Stage 10-2016-7033189
    Filed on 2016-11-28
    Status: Issued
  • Mexico
    National Stage MX/a/2016/015383
    Filed on 2015-05-29
    Status: Issued
  • Saudi Arabia
    National Stage 516380394
    Filed on 2015-05-29
    Status: Issued
  • US Patent 10,174,098
    Filed on 2016-11-23
    Status: Issued
  • Hong Kong
    European patent (EP) 17109823.5
    Filed on 2017-09-27
    Status: Issued
  • US Patent 10,870,687
    Filed on 2018-11-30
    Status: Issued
  • European Patent
    Divisional (DIV) 19217074.4
    Filed on 2019-12-17
    Status: Issued
  • Australia
    Divisional (DIV) 2019283892
    Filed on 2019-12-18
    Status: Issued
  • Albania
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Austria
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Belgium
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Bulgaria
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Switzerland
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Cyprus
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Czech Republic
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Germany
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Denmark
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Estonia
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Spain
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Finland
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • France
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • United Kingdom
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Greece
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Croatia
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Hungary
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Ireland
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Iceland
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Italy
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Lithuania
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Luxembourg
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Latvia
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • North Macedonia
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Malta
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • The Netherlands
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Norway
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Poland
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Portugal
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Romania
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Sweden
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Slovenia
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Slovakia
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • San Marino
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Turkey
    European patent (EP) 15729004.0
    Filed on 2015-05-29
    Status: Issued
  • Japan
    Divisional (DIV) 2020-127833
    Filed on 2020-07-29
    Status: Issued
  • Saudi Arabia
    Divisional (DIV) 520412601
    Filed on 2020-08-06
    Status: Abandoned
  • Hong Kong
    European patent (EP) 42020020661.3
    Filed on 2020-11-24
    Status: Pending
  • Mexico
    Divisional (DIV) MX/a/2020/010035
    Filed on 2020-09-24
    Status: Pending
  • US Patent 11,434,272
    Filed on 2020-11-23
    Status: Issued
  • Australia
    Divisional (DIV) 2021202227
    Filed on 2021-04-13
    Status: Issued
  • China
    Divisional (DIV) 202110399056.9
    Filed on 2021-04-14
    Status: Issued
  • Israel
    Divisional (DIV) 282518
    Filed on 2021-04-21
    Status: Issued
  • Hong Kong
    China Patent (CN) 42022046605.6
    Filed on 2022-01-19
    Status: Issued
  • Japan
    Divisional (DIV) 2021-203953
    Filed on 2021-12-16
    Status: Issued
  • Israel
    Divisional (DIV) 290655
    Filed on 2022-02-16
    Status: Issued
  • US
    Continuation (CON) 17/816,496
    Filed on 2022-08-01
    Status: Pending
  • South Korea
    Divisional (DIV) 10-2022-7032043
    Filed on 2022-09-15
    Status: Issued
  • Australia
    Divisional (DIV) 2023200608
    Filed on 2023-02-06
    Status: Issued
  • Japan
    Divisional (DIV) 2023-091878
    Filed on 2023-06-02
    Status: Issued

Publications

Collaborations

  • Licensing
  • Collaboration

Collaboration Description

  • Researchers at the NCI seek licensing and/or co-development research collaborations for a TCR with high-avidity recognition of the E7 oncoprotein to treat HPV-positive malignancies.
Date Published